Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Fig. 1

Experimental protocols. Freshly harvested 4 T1 tumor cells were injected into the mammary fat pads of syngeneic (Balb/C) mice. One week after transplantation, the mice were randomized into four treatment groups: (i) vehicle (saline), (ii) CAELYX®, (iii) LTX-315, and (iv) LTX-315 + CAELYX® for experiment 1 and (i) vehicle (saline) + surgery, (ii) CAELYX® + surgery, (iii) LTX-315 + surgery, and (iv) LTX-315 + CAELYX® + surgery for experiment 2

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us